Stock Detail
DYNAVAX TECHNOLOGIES CORPORATION
Sector: Biotechnology
Latest Quote @ Tue May 5 07:49:49 (15 min delayed)
| $2.37 |
$2.50 |
$2.48 |
-0.03 |
-1.20% |
1.81M |
Last Day's Data
| $2.48 |
$2.52 |
$0.00 |
0.00% |
0.00 |
$2.51 |
| $2.51 |
$2.44 |
1.00 |
453.57M |
1.73M |
0.00 |
Pivot Table
| R2 |
R1 |
Pivot |
S1 |
S2 |
| 2.56 |
2.52 |
2.48 |
2.44 |
2.40 |
Stock Profile
Dynavax Technologies Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases. The company's clinical development programs are based on immunostimulatory sequences, which are short DNA sequences that enable the immune system to fight disease and control chronic inflammation. Its pipeline includes TOLAMBA, a ragweed allergy immunotherapeutic, which is in a Phase II/III clinical trial and in a supportive clinical trial in ragweed allergic children; HEPLISAV, a hepatitis B vaccine in a pivotal Phase III clinical trial; a cancer therapy in a Phase II clinical trial; and an asthma immunotherapeutic that has shown preliminary safety and pharmacology in a Phase IIa clinical trial. The company was founded in August 1996 as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax is based in Berkeley, California.
